Modified GRF (1–29) / Hexarelin Blend is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Modified GRF (1–29) and Hexarelin. Modified GRF (1–29) is a stabilized analog of growth hormone–releasing hormone (GHRH), while Hexarelin is a potent growth hormone secretagogue receptor (GHS-R) agonist derived from the growth hormone–releasing peptide family. Together, this blend is formulated for laboratory research focused on growth hormone release dynamics, receptor activation pathways, and coordinated endocrine signaling mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, Modified GRF (1–29) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a short duration of activity. Hexarelin has been extensively researched for its strong receptor affinity and its role in stimulating growth hormone secretion via ghrelin receptor pathways. The combination allows researchers to examine complementary mechanisms involved in growth hormone pulsatility, secretion amplitude, and integrated pituitary response models.
Currently, the Modified GRF (1–29) / Hexarelin Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic signaling, cardiovascular-related research pathways, and circadian growth hormone release patterns. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Modified GRF (1-29), Hexarelin Blend is structured for laboratory research investigating growth hormone axis signaling, hypothalamic–pituitary communication, and downstream endocrine biomarker behavior under controlled experimental conditions. By pairing a growth hormone–releasing hormone (GHRH) analog with a growth hormone secretagogue, researchers can evaluate how complementary signaling inputs influence pulsatile GH release patterns and associated marker dynamics.
Combination peptide models can provide higher-resolution insight into pathway interaction effects, but they also raise the bar for experimental discipline. The most defensible datasets typically come from protocols that pre-define primary endpoints, standardize sampling cadence, and control confounders such as circadian timing, nutritional inputs, activity exposure, and stress load.
Modified GRF (1-29), Hexarelin Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Modified GRF (1-29) + Hexarelin |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Modified GRF (1-29) is commonly referenced in peptide research as a GHRH analog used to study growth hormone release signaling through hypothalamic–pituitary axis pathways. In research settings, it is often positioned as an upstream signal input, helping investigators evaluate pulse-timing behavior and downstream endocrine marker responses in time-series models.
Hexarelin is a growth hormone secretagogue studied for its activity within ghrelin receptor–associated pathways and related pituitary response signaling. In controlled experiments, it may be used to explore the intensity and shape of hormone-response profiles and to examine how secretagogue-driven inputs interact with upstream GHRH pathway stimulation.
In blended protocols, researchers can evaluate whether dual-pathway signaling produces differentiable changes in marker behavior compared to single-input conditions. Well-structured studies often include single-peptide controls, consistent sampling windows, and clear definitions for what qualifies as an actionable signal versus background biological variance.
For single-compound reference, researchers can review: CJC-1295 (without DAC) (commonly associated with Modified GRF research) and Hexarelin.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
This blend is frequently used in experimental models analyzing GH-axis pulse architecture, including timing, amplitude, and frequency across defined sampling windows. Researchers may compare response curves between blended and single-input conditions to characterize pathway interaction effects.
Modified GRF (1-29) provides an upstream signaling input, while Hexarelin provides secretagogue-driven stimulation through ghrelin receptor–associated pathways. In combination, these inputs can be used to explore how upstream and downstream signaling components coordinate in endocrine models.
GH-axis studies often include downstream marker panels and time-based sampling to evaluate how hormone signaling correlates with measured biomarkers. In blended protocols, researchers may evaluate whether marker patterns show different trajectories compared to single-pathway designs.
High-quality research programs frequently include single-compound controls and placebo/vehicle controls alongside blend conditions. This design improves attribution, reduces interpretability risk, and enables more confident decisions about subsequent study phases.
The Modified GRF (1-29), Hexarelin Blend should be handled according to standard laboratory peptide SOPs, with emphasis on contamination prevention, moisture control, and traceable documentation. Because GH-axis outcomes are sensitive to timing and environmental conditions, strict consistency in sample collection and experimental inputs is typically required.
Protocol Design Considerations: GH-axis experiments are sensitive to circadian timing, baseline metabolic phenotype, sleep disruption, stress exposure, and environmental variability. Tight controls and standardized sampling windows strengthen reproducibility and interpretation.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend includes a Certificate of Analysis documenting peptide identity and quality parameters. These analytical reports support procurement verification, internal QA documentation, and reproducibility tracking across research studies.
Laboratories sourcing peptide blends for endocrine signaling research typically prioritize lot traceability, consistent analytical documentation, and reliable synthesis standards. Nordsci Peptides provides research-grade peptide materials supported by Certificates of Analysis and standardized manufacturing practices designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
